Sending a bone marrow aspirate to an external laboratory sounds straightforward until the courier calls at 7 a.m. to ask whether the specimen is classified as a Category B biological substance under IATA P650, and your answer determines whether the package gets loaded or held at Narita. For many clinicians in Japan, the referral workflow is pieced together from internal memos, verbal hand-offs from senior colleagues, and the occasional phone call to a lab coordinator who is also managing three other urgent samples. This guide exists to compress that learning curve. It covers everything from the moment the needle is withdrawn to the moment a structured report lands in your hospital information system, with particular attention to the regulatory checkpoints that are specific to Japan's Pharmaceutical and Medical Device Act framework and the guidelines issued by the Japanese Society of Laboratory Hematology.
Why the referral pathway in Japan is different from what overseas training prepared you for ¶
Many physicians who trained abroad — or who learned hematology referral workflows from translated American or European textbooks — arrive at the Japan-specific system expecting it to mirror what they already know. It does not, in several meaningful ways. The Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (the PMD Act, revised in 2014 and amended multiple times since) places specific obligations on the originating institution when biological specimens cross prefectural lines or enter a third-party processing facility. Practically speaking, this means the referring physician or the hospital's clinical laboratory technologist (臨床検査技師) carries formal documentation responsibility that, in some other systems, falls entirely to the receiving lab. Additionally, the Japanese Society of Laboratory Hematology's specimen handling guidelines specify a maximum transit window of 24 hours from collection to analysis initiation for aspirate samples intended for flow cytometry immunophenotyping — a tighter window than the 48-hour standard often cited in North American protocols. Knowing this before collection saves the sample.
Sample preparation at the collection site: the decisions that determine downstream quality ¶
The single biggest predictor of a usable aspirate result is what happens in the first ten minutes after collection. For morphology smears destined for external review, the standard recommendation is to prepare a minimum of eight to ten air-dried smears immediately at the bedside, before the sample is anticoagulated. Sodium heparin (lithium heparin is acceptable) at a concentration of 10 IU per mL is the anticoagulant of choice for flow cytometry panels; EDTA is acceptable for cytogenetic FISH studies but is not ideal if the lab will be performing viability-dependent assays. Volume matters: most external labs in Japan request a minimum of 3 mL in an anticoagulated tube for a standard immunophenotyping panel, and 5 mL if concurrent cytogenetic analysis is ordered. If the marrow is hypocellular or the yield is unexpectedly poor, contact the receiving lab before dispatch — most have a modified low-volume protocol and will adjust the panel rather than reject the sample outright. Label every tube at the bedside with the patient ID, collection time to the minute, and the anticoagulant type. Collection time to the minute is not bureaucratic pedantry; it directly affects the viability calculation in the flow cytometry report.
Packaging and transport: the cold-chain rules that actually govern a marrow aspirate in Japan ¶
Bone marrow aspirates shipped between Japanese medical institutions are classified under IATA Packing Instruction 650 (P650) as Category B biological substances (UN3373) unless the sample is known or suspected to contain a pathogen classified at biosafety level 3 or above, in which case Category A rules apply. For the overwhelming majority of diagnostic aspirates — patients being worked up for MDS, lymphoma staging, aplastic anemia — UN3373 applies. The packaging requirement under P650 is a triple-layer system: a watertight primary container (the specimen tube), an absorbent secondary container, and a rigid outer box meeting drop and pressure specifications. Commercial clinical specimen shipping kits sold by Yamato Transport's medical division (クロネコメディカル便) and Sagawa Express's clinical logistics arm are pre-certified for UN3373 and are widely used by hospitals across Japan. Temperature is the other critical variable. Most external labs require the aspirate to arrive at 4–8°C, which means a validated cold pack configuration rather than a simple ice bag. Do not freeze unless the receiving lab has explicitly requested a frozen specimen for a specific molecular assay. Freezing destroys cell morphology and renders flow cytometry immunophenotyping impossible.
Documentation: the paperwork set that must accompany every external aspirate referral ¶
The Japanese referral documentation stack for an external aspirate has four components, and missing any one of them can result in processing delays of one to three business days while the lab waits for a corrected submission. First, the 検査依頼書 (laboratory request form): this must include the patient's date of birth, the referring physician's medical license number, the institution's clinical laboratory permit number, the specific tests requested by name and code, and the indication. Second, the informed consent form confirming the patient has agreed to external laboratory processing — this is a PMD Act requirement and is non-negotiable. Third, the biological specimen transport declaration, signed by the clinical laboratory technologist who prepared the sample. Fourth, if the patient has a known or suspected infectious disease (HIV, HBV, HCV, HTLV-1), an additional biohazard notification form is required by most receiving labs and is strongly recommended even when not formally required. Some hospitals transmit the request form electronically via the SS-MIX2 standardized format, which the majority of major external clinical laboratories in Japan now accept. If your hospital is not yet on SS-MIX2, a faxed or mailed paper form remains fully valid.
Turnaround times by assay type: what a realistic timeline looks like ¶
Turnaround time varies substantially by the assay, and conflating them is a common source of frustration between clinical teams and laboratory coordinators. Morphology review with differential count typically returns in one to two business days from receipt. Multicolor flow cytometry immunophenotyping panels — for example, a 10-color panel covering B-cell, T-cell, and myeloid lineage markers — generally return in two to three business days, reflecting the time required for antibody incubation, acquisition on the cytometer, and gating analysis by a certified laboratory hematologist. Conventional karyotyping (G-banding) requires cell culture and is the longest component: expect 14 to 21 calendar days. FISH for specific loci (BCR-ABL1, MLL rearrangements, del(5q), del(17p)) returns faster, usually in five to seven business days. Next-generation sequencing panels for myeloid mutations — offered by a growing number of external labs including SRL, LSI Medience, and Falco Biosystems — range from 10 to 21 business days depending on panel size and whether the lab is running the sample in a batch or on a priority track. Ask specifically about batch versus priority scheduling when turnaround is clinically urgent.
Reading the processed report: what the sections mean and where the clinical weight actually sits ¶
A full external aspirate report from a Japanese reference laboratory typically arrives as a structured PDF via secure electronic delivery (多くの場合, 電子カルテ連携 or a lab-specific secure portal) and is organized into five to six sections. The macroscopic and smear adequacy note comes first and tells you whether the sample met minimum cellularity thresholds for each assay. If a test was not performed due to poor sample quality, this section explains why. The morphology section contains the differential count expressed as percentages of 500 nucleated cells, with the pathologist's narrative describing blast morphology, dysplastic changes, and any incidental findings. The flow cytometry section presents each antibody combination as a dot plot summary table and gives percentages for each immunophenotypically defined population; the narrative will flag any population that deviates from normal distribution and will specify whether an aberrant immunophenotype meets criteria for monoclonal expansion. Cytogenetics results follow the ISCN nomenclature standard. The integrated interpretation at the end is where the reporting hematologist or hematopathologist synthesizes all modalities; this section carries diagnostic weight and is the appropriate section to cite when documenting a clinical decision. If anything in the integrated interpretation surprises you or conflicts with your clinical picture, most labs provide a direct consultation line staffed during business hours (平日 9:00–17:00) — use it.
Common errors and the corrections that actually fix them ¶
Tracking failure modes across referral workflows reveals a consistent short list. The most frequent is insufficient sample volume combined with too many tests ordered: a 2 mL aspirate cannot simultaneously support a full 12-marker flow panel, FISH for four loci, and karyotyping. When in doubt, call the lab before the procedure and ask for test prioritization guidance given the expected yield. The second most common error is a collection-to-dispatch gap exceeding four hours at room temperature, usually caused by delays in obtaining the signed informed consent form after the fact. Solve this by obtaining consent before the procedure, not after. Third: smears prepared after anticoagulation rather than before. Anticoagulated blood dilutes marrow particles and disrupts the morphological architecture that pathologists rely on for dysplasia assessment. Fourth: the referring physician's license number missing from the 検査依頼書, which under Japanese clinical laboratory law (臨床検査技師等に関する法律) makes the form legally incomplete. Each of these errors has a structural fix — a pre-procedure checklist specific to marrow referrals, shared between the hematology team and the clinical laboratory technologist, eliminates most of them without adding meaningful time to the workflow.
The referral workflow for bone marrow aspirates in Japan is more codified than it sometimes appears from the inside of a busy hematology unit. The PMD Act documentation requirements, the 24-hour transit window, the UN3373 packaging rules, and the structured report format all exist for reasons that connect directly to result validity and patient safety. Running through this process once with a laboratory coordinator from the receiving lab before you send your first external sample is the single most efficient use of thirty minutes in this context — most major Japanese reference labs offer exactly this kind of pre-referral orientation call, and it tends to eliminate the 7 a.m. courier phone call entirely.